atorvastatin reduces plasma levels of chemokine (cxcl10) in patients with crohns disease阿托伐他汀能降低血浆水平的趋化因子(cxcl10)节段性回肠炎患者.pdfVIP

Atorvastatin Reduces Plasma Levels of Chemokine (CXCL10) in Patients with Crohn’s Disease 1 2 Olof Grip *, Sabina Janciauskiene ¨ ¨ 1 Division of Gastroenterology and Hepatology, Department of Clinical Sciences Malmo, Lund University, University Hospital MAS, Malmo, Sweden, 2 Chronic ¨ ¨ Inflammatory and Degenerative Diseases Research Unit, Department of Clinical Sciences Malmo, Lund University, University Hospital MAS, Malmo, Sweden Abstract Background: In Crohn’s disease high tissue expression and serum levels of chemokines and their receptors are known to correlate with disease activity. Because statins can reduce chemokine expression in patients with coronary diseases, we wanted to test whether this can be achieved in patients with Crohn’s disease. Methodology/Principal Findings: We investigated plasma levels of chemokines (CCL2, CCL4, CCL11, CCL13, CCL17, CCL22, CCL26, CXCL8, CXCL10) and endothelial cytokines (sP-selectin, sE-selectin, sICAM-3, thrombomodulin) in ten Crohn’s disease patients before and after thirteen weeks’ daily treatment with 80 mg atorvastatin. Of the 13 substances investigated, only CXCL10 was found to be significantly reduced (by 34%, p = 0.026) in all of the treated patients. Levels of CXCL10 correlated with C-reactive protein (r = 0.82, p,0.01). Conclusions/Significance: CXCL10 is a ligand for the CXCR3 receptor, the activation of which results in the recruitment of T lymphocytes and the perpetuation of mucosal inflammation. Hence the reduction of plasma CXCL10 levels by atorvastatin may repr